

Value Line 201
Understanding a Company Report

Value Line 201

Understanding A Company Report

June 15, 2022

Presented by Marty Eckerle

Director – OKI Tri-State Chapter

mjeckerle@gmail.com

In cooperation with the Portland Chapter of Oregon



Disclaimer

- The information in this presentation is for educational purposes only and is not intended to be a recommendation to purchase or sell any of the stocks, mutual funds, or other securities that may be referenced. The securities of companies referenced or featured in the seminar materials are for illustrative purposes only and are not to be considered endorsed or recommended for purchase or sale by BetterInvesting™ / National Association of Investors™. The views expressed are those of the instructors, commentators, guests and participants, as the case may be, and do not necessarily represent those of BetterInvesting. Investors should conduct their own review and analysis of any company of interest before making an investment decision.
- Securities discussed may be held by the instructors in their own personal portfolios or in those of their clients. BetterInvesting presenters and volunteers are held to a strict code of conduct that precludes benefitting financially from educational presentations or public activities via any BetterInvesting programs, events and/or educational sessions in which they participate. Any violation is strictly prohibited and should be reported to the CEO of BetterInvesting or the Director of Chapter Relations.
- This presentation may contain images of websites and products or services not endorsed by BetterInvesting. The presenter is not endorsing or promoting the use of these websites, products or services.
- National Association of Investors™, BetterInvesting™ and the BetterInvesting™ Icon are trademarks/registered trademarks. All rights reserved. © 2021 BetterInvesting™.
- This Session will be recorded. If you wish a link, please add a request in the questions box.

What We Will Cover

- We will discuss most of the data available on the survey.
 - Including each measure of the Value Line Ranking System.
- A few Formula using Value Line data to help with your SSG judgment.
- Our backroom staff is ready to answer your questions or hold them for me to answer as we progress through the class.

Handouts

- Reading the Value Line Report – ver. 2021.
- Value Line Home Depot Sample Page.
- Statistical Array Definitions.
- A one page per slide color PDF of this class.
- A three page per slide color PDF.

The Value Line Investment Survey® Sample Page

9 9 9 9 9 9 Relative P/E ratio — the stock's current P/E divided by the current median P/E for the approximately 1,700 stocks under Value Line review.

SAMPLE RESEARCH REPORT

SAMPLE RESEARCH REPORT

- Nalue Line Ranks the rank for Timeliness: the rank for Safety: the Technical rank. Beta, the stock's sensitivity to
- the stock's 3- to 5-year projected target price, with "cash flow" projected out over the same period.
- Relative Price Strength describes the stock's past price performance relative to the Value Line (Arithmetic Average of approximately 1,700 stocks. (A rising line indicates the stock price has been rising more than the Valu
- Recent Price Price as of the date listed on page 2 under Index to Stocks of this issue's Summary & Index
- P/E Ratio the recent price divided by the latest six months' earnings per share plus earnings estimated for th
- Trailing and Median P/E the first is the recent price divided by the sum of reported earnings for the past four reported quarters; the second is an average of the price/earnings ratios over the past 10 years.


- 3- to 5-year Target Price Range the range in which a stock price is likely to trade in the 3- to 5-year projection period

- months on a regular schedule. Supplementary reports are issued when there is important news
- Value Line Ratings for Financial Strength, Price Stability, Price Growth Persistence, and Earnings Predictability
- Footnotes explain a number of things, such as the way earnings are reported, whether basic or diluted
- (B) Quarterly Sales are shown on a gross basis. Quarterly earnings on a per-share basis (estimates in bold type). Quarterly Dividends Paid are actual payments. The total of dividends paid in four quarters may not equal the figure shown in the annual series on dividends declared in the Historical and Statistical Arrays. (Sometimes a dividend declared at the end of the year will be paid in the first quarter of the following year.)
- Annual Rates of Change (on a compound per-share basis). Actual for each of the past 5 and 10 years
- Historical Array historical financial data appear in regular type.
- 19 Projected stock price in 3 to 5 years. Also, the total expected percent gain/loss before dividends and the Annual Tota
- 20 18-Month Target Price Range A quantitative measure that seeks to predict a stock's price over an 18-month


Statistical Array — Important historiand projected numerical information. The numbers are for fiscal years if used by the company. Historical financial data appe

company, Historical martical data appling regular type. Value Line estimates: projections appear in hold flatics. The quarterly figures in the lower left of the page indicate whether calendar or its years are used. The Foothotes indicate

The Graph




The Graph Cont.



The "Cash Flow" Line




Price Earnings Ratios and More





Common Shs Outst'g E	2525.0	
Avg Ann'l P/E Ratio	18.0	
Relative P/E Ratio	1.00	
Avg Ann'l Div'd Yield	26%	
Sales (\$mill) A	107500	12
Operating Margin	44.0%	12
Depreciation (\$mill)	8250	

Legends, Target Price Ranges & Projections



Statistical ArrayHistorical Results and Estimates

24-2	© VALUE LINE PUB. LLC	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
42.	Sales per sh A	37.10	35.25	31.40	31.17	30.64	28.50	26.56	25.44	26.71	25.28	24.19	23.87	22.49	22.47	23.02	21.51	18.43	16.98
15.	"Cash Flow" per sh		12.50	10.85	11.52	8.35	7.64	7.50	6.95	7.26	7.08	6.48	6.25	5.92	5.69	5.70	5.23	4.60	4.25
12	Earnings per sh A B	10.15	9.50	8.03	8.68	5.61	5.41	5.93	5.48	5.70	5.52	5.10	5.00	4.76	4.63	4.57	4.15	3.76	3.50
5.	Div'ds Decl'd per sh Ca		4.25	3.98	3.75	3.54	3.32	3.15	2.95	2.76	2.59	2.40	2.25	2.11	1.93	1.80	1.62	1.46	1.28
1.	Cap'l Spending per sh	1.50	1.50	1.10	1.33	1.38	1.22	1.19	1.26	1.33	1.27	1.06	1.06	.87	.86	1.11	1.04	.92	.88
49	Book Value per sh. D	35.10	30.75	27.15	22.59	22.44	22.43	26.02	25.83	25.06	26.25	23.33	20.95	20.66	18.37	15.35	15.25	13.59	12.73
252	Common Shs Outst'g E	2580.0	2600.0	2630.0	2632.5	2662.3	2682.5	2706.5	2755.0	2783.3	2820.6	2778.5	2724.4	2738.1	2754.3	2769.2	2840.2	2893.2	2974.5
10	Avg Ann'i P/E Ratio	ures are	Bold fig	18.2	15.6	23.7	23.9	19.1	18.2	17.7	15.6	13.1	12.7	13.1	12.5	14.3	15.4	16.6	18.5
1.	Helative P/E Hatio		Value	89	.83	1.28	1.20	1.00	.92	.93	.88	.83	.80	.83	.83	.86	.82	.90	.99
2.6	Avg Ann'l Div'd Yield	estimates		2.7%	2.8%	2.7%	2.6%	2.8%	3.0%	2.7%	3.0%	3.6%	3.5%	3.4%	3.3%	2.8%	2.5%	2.3%	2.0%
1075	Sales (\$mill) A	95750	91650	82584	82059	81581	76450	71890	70074	74331	71312	67224	65030	S - 4					
44.0	Operating Margin	43.5%	43.0%	42.0%	46.3%	33.1%	31.7%	34.6%	31.1%	33.7%	33.3%	35.7%	32.3%						
82	Depreciation (\$mill)	7500	7250	7050	7009.0	6929.0	5642.0	3754.0	3746.0	3895.0	4104.0	3666.0	3158.0						
315	Net Profit (\$mill)	26500	25250	21433	23310	15297	14856	16540	15409	16323	15876	14345	13867						
19.0	Income Tax Rate	18.0%	17.5%	15.7%	17.4%	15.0%	15.9%	16.5%	19.7%	20.6%	17.2%	23.1%	20.1%						
29.	Net Profit Margin	27.7%	27.6%	26.0%	28.4%	18.8%	19.4%	23.0%	22.0%	22.0%	22.3%	21.3%	21.3%						
750	Working Cap'l (\$mill)	34250	28500	19750	9310.0	14803	12551	38745	32463	34226	30732	21854	31505						
200	Long-Term Debt (\$mill)	23000	24000	32500	26494	27684	30675	22442	12857	15122	13328	11489	12969						
1250	Shr. Equity (\$mill)	90500	80000	71400	59471	59752	60160	70418	71150	69752	74053	64826	57080						
20.0	Return on Total Cap'l	23.0%	22.5%	21.0%	27.3%	18.1%	16.9%	18.2%	18.6%	19.5%	18.4%	19.1%	20.2%						
25.0	Return on Shr. Equity	29.5%	31.5%	30.0%	39.2%	25.6%	24.7%	23.5%	21.7%	23.4%	21.4%	22.1%	24.3%						
13.	Retained to Com Eq	16.0%	17.5%	17.0%	22.5%	9.7%	9.8%	11.2%	10.2%	12.3%	11.6%	11.9%	13.5%						
4	All Div'ds to Net Prof	45%	44%	43%	43%	62%	60%	52%	53%	48%	46%	46%	44%						

Capital Structure – Current Position Annual & Growth Rates

CAPITAL STRUCTURE as of 9/27/20
Total Debt \$37,758 mill. Due in 5 Yrs \$17,104 mill.
LT Debt \$32,680 mill. LT Interest \$152.3 mill.
(34% of Capital)
Leases, Uncapitalized Annual rentals \$215 mill.
Pension Assets-12/19 \$32.2 bill. Oblig. \$37.2 bill.
Preferred Stock None
Common Stock 2,632,542,672 shares as of 10/19/20
MARKET CAP: \$365 billion (Large Cap)

CURRENT POSITION (SMILL.)	2018	2019	9/27/20
Cash Assets Receivables	19687 14098	19287 14481	30781 14579
Inventory (FIFO) Other Current Assets	8599 3649 46033	9020 2486 45274	9599 2619
Accts Payable Debt Due	7537 2796	8544 1202	57578 7044 5078
Other Current Liab.	20897 31230	2621B 35964	26725 38847

6	ANNUAL RATES	Past	Past	Est'd '17-'19
Section 1	of change (per sh)	10 Yrs.	5 Yrs.	to 24-26
_	Sales	3.0%	3.5%	5.0%
	"Cash Flow"	5.0%	5.5%	8.5%
	Earnings	4.0%	4.0%	10.0%
	Dividends	7.0%	6.5%	7.5%
	Book Value	3.5%	-2.0%	11.0%

Company **Ratings**

Company's Financial Strength	A++	all h
Stock's Price Stability	100	CP.
Price Growth Persistence	85	W
Earnings Predictability	75	-100

Footnotes

(A) Years end on the last Sunday in December. d71¢; 4th qtr.'17, d\$5.73 (due to tax reform.); (B) Diluted earnings. Excludes nonrecurring: '19 (\$3.05)' '20, (\$2.52). GAAP from 2015- '04, d26¢; '05, d4¢; '06, d3¢; '07, d52¢; '09, 2018. Next earnings report due late April. "10, 2c; "11, d\$1.51; "12, d\$1.24; "13,

(C) Dividends historically paid: March, June,

September, and December.

Dividend reinv estment plan available.

(D) Includes intangibles. On 12/31/19: \$81.3 billion, \$30.76 a share. (E) In millions.

Quarterly Sales, Earnings & **Dividends**

Cal- endar			ALES (\$ m Sep.Per	ill.) ^A Dec.Per	Full Year
2018	20009	20831	20348	20393	81581
2019	20021	20562	20729	20747	82059
2020		18336	21082	22475	82584
2021	22000	22250	23500	23900	91650
2022	23000	23250	24500	25000	95750
Cal-			ER SHARE		Full
endar	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Year
2018	1.60	1.45	1.44	1.12	5.61
2019	2.10	2.58	2.12	1.88	8.68
2020	2.30	1.67	2.20	1.86	8.03
2021	2.40	2.40	2.40	2.30	9.50
2022	2.55	2.55	2.55	2.50	10.15
Cal-	QUAR	TERLY DIV	VIDENDS P	AID C.	Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2017	.80	.84	.84	.84	3.32
2018	.84	.90	.90	.90	3.54
2019	.90	.95	.95	.95	3.75
2020 2021	.95	1.01	1.01	1.01	3.98



Business Information

BUSINESS: Johnson & Johnson is engaged in the research & development, manufacture, and sale of a broad range of products in the healthcare field. It operates three business segments: Consumer (baby care, beauty, skin care, oral care, wound care, etc.), Pharmaceutical (antintective, antipsychotic, contraceptive, dermatology, gastrointestinal, etc.), and Medical Devices (orthopedic, surgery, Interventional solutions, and eye health fields). Employs approximately 132,200. Officers & directors less than 1.0% of common stock; Vanguard Group, 8.7%; BlackRock, 7.3%; State Street, 5.8%. (3/20 Proxy). Challman & CEO: Alex Gorsky. Inc.: NJ. Address: One Johnson & Johnson Plaza, New Brunswick, NJ 08933. Telephone: 732-524-0400. Internet: www.jnj.com.

- 1. What does this company do?
- 2. Employment information.
- 3. Insider Ownership.
- 4. List of fund ownership.
- 5. Chairman & CEO.
- Company address with phone #.
- 7. Webpage URL.

Analyst's Commentary (Item 13)

Johnson & Johnson is making headlines. The company announced the muchanticipated results of its Phase III trial for its COVID-19 vaccine. This showed 66% overall efficacy in blocking moderate-tosevere forms of the disease and 85% efficacy in severe forms. While this comes up short of the efficacy shown by the Moderna and Pfizer/BioNTech vaccines, we view the data as favorable, especially when considering the overwhelming demand as well as the advantage that J&J's vaccine has of requiring only one shot. Wall Street did not seem to share our optimism, however, and the stock slipped on the news. Still, J&J planned to file in early February for emergency use authorization with the Food & Drug Administration.

The world's largest healthcare company reported better-than-expected fourth-quarter results. Share earnings came in at \$1.86, a couple of pennies off the year-earlier tally, but about a nickel ahead of the consensus estimate. Although margins remained under fairly heavy pressure, sales increased a better-than-anticipated 8.3%, roughly double our estimate, thanks to ongoing momentum from

the Pharmaceutical business.

We've upped our 2021 estimates. Guidance was solid, with management saying that it is looking for sales to tally between \$90.5 billion and \$91.7 billion for all of 2021, pointing to a 9.5%-11.0% rise. From a bottom-line perspective, it is now calling for EPS of \$9.40 to \$9.60. And this was before the release of the aforementioned results of the company's COVID-19 trials.-Adding it all up, we currently look for J&J to earn \$9.50 a share, on an 11% uptick in sales. The company should continue to do well with its Pharmaceutical portfolio, and we expect the other businesses to gain traction as the year progresses. Too, we see margin improvement accelerating in the second half of the year.

The stock has done well since our November report despite the abovementioned pullback. We continue to think that it offers worthwhile three- to five-year total return prospects, especially on a risk-adjusted basis. J&J's COVID-19 vaccine is a plus in our eyes, and investors should consider buying on dips. These shares are now an Average selection for Timeliness.

Andre J. Costanza February 12, 2021


THE RANKING SYSTEM

The Ranking System

Regular Edition Ranking

Mid and Small Cap Ranking





Timeliness

- The Value Line Timeliness Rank measures predicted relative price performance of a company relative to the approximately 1,700 stocks during the next six to 12 months on a scale from 1 (Highest) to 5 (Lowest).
 - Changes in the Timeliness ranks can be caused by:
 - New earnings reports or company announcements.
 - Changes in the price movement of one stock relative to the approximately 1,700 other stocks in the publication.
 - Shifts in the relative positions of other stocks.

Timeliness Rank System

- Rank 1 (Highest) Rank 2 (Above Average)
 - These stocks, as a group, are expected to outperform the Value Line universe during the next six to 12 months.
 - 100 stocks are in Rank 1 and 300 are in Rank 2.
- Rank 3 (Average)
 - These stocks, as a group, are expected to have relative price performance in line with the Value Line universe.
 - About 1100 stocks fall into this rank.
- Rank 4 (Below Average) Rank 5 (Lowest)
 - Rank 4 stocks, as a group, (about 100) are expected to have below-average relative price performance.
 - Rank 5 stocks, as a group, are out of favor regarding the Timeliness System (100 stocks).

Safety

 A second and crucial investment criterion is the Safety rank assigned by Value Line to each of the approximately 1,700 stocks.

- The Value Line Safety Rank measures the total risk of a stock relative to the approximately 1,700 other stocks.
 - It includes a stock's Price Stability rank and the Financial Strength rating of a company.
- Safety ranks are also given on a scale from 1 (Safest) to 5 (Riskiest).

Technical

- Technical Rank is Value Line's proprietary ranking of estimated stock price performance relative to the overall market in the next three to six months.
- It is based on a complex analysis of the stock's relative price performance during the previous 52-weeks.
- Unlike the Timeliness Rank, earnings are not a factor in the Technical Rank.

Beta

- Beta is a relative measure of the historical sensitivity of the stock's price to overall fluctuations in the New York Stock Exchange Composite Index.
- A Beta of 1.50 indicates a stock tends to rise (or fall) 50% more than the index just mentioned.
- The Betas are adjusted for their long-term tendency to converge toward 1.00.

Performance – Mid and Small Cap Survey

- The Performance Rank is a similar calculation to Timeliness that is designed to predict the future relative price performance of the more than 3,300 stocks followed in Value Line's overall database than are not included in the Standard edition.
- The Performance Rank is a purely quantitative measure that is based on past earnings and price performance data.

FORMULA TO ASSIST YOUR RESEARCH RESULTS

Formula for Calculating Forecast Revenue or Earnings Per Share Growth Rate Percentage

- On a financial calculator, input the average of the 3 most recent completed years of revenue or earnings as the 'present value.'
- Secondly input the projected revenue or earnings as the 'future value.'
- Third input the number of years.
 - Subtract the mid-year of the most recent three years from the mid-year of the projected year and input the result as the 'number' of years.
 - Finally, select 'compute' to arrive at a calculated percent of projected growth.
 - PC Location for the Toolkit Calculator: Open your PC main directory. Scroll to Program Files (x86), then the IClub Central folder' and next the Toolkit folder. Inside it you will see a file titled 'IWcalc.exe'.

Valuable Formula for use in the Preferred

Procedure

- To calculate Forecast PTP Margin
 - Net Profit Margin ÷ One -Income Tax Rate
 - $29.3 \div (1-19)$ or .81 = 36.2
- To calculate exact Forecast Common Shares Outstanding
 - Net Profit \$ ÷ EPS
 - 31500 ÷ 12.25 = 25714

© VALUE LINE PUB. LLC	24-26
Sales per sh A	42.55
"Cash Flow" per sh	15.75
Earnings per sh AB	12.25
Div'ds Decl'd per sh C	5.50
Cap'l Spending per sh	1.65
Book Value per sh D	49.50
Common Shs Outst'g E	2525.0
Avg Ann'l P/E Ratio	18.0
Relative P/E Ratio	1.00
Avg Ann'l Div'd Yield	2.5%
Sales (\$mill) A	107500
Operating Margin	44.0%
Depreciation (\$mill)	8250
Net Profit (\$mill)	31500
Income Tax Rate	19.0%
Net Profit Margin	29.3%
Working Cap'l (\$mill)	75000
Long Torm Dobt /Émill\	20,000

Sources

The handouts as I previously mentioned.

- Value Line Tool Guides.
 - An exceptional source directly available at Value Line.

- Saul Seinberg's "Playing the Piano with Both Hands.
 - https://www.betterinvesting.org/chapters/online/news-articles.

Special Value Line Pricing Offer

- Value Line has expressed appreciation for our presenting this class to you.
- They have offered to any new or renewing customers special pricing.
- To take advantage, please contact Chelsea Denunzioi at (212) 907-1540 or email <u>cdenunzio@valueline.com</u>.
- Please mention the Value Line Class presented by Marty Eckerle of the OKI Tri-State and Portland Chapters of BetterInvesting.

Value Line 201 – QUESTIONS?

Understanding A Value Line Company Report

June 15, 2022

Presented by Marty Eckerle

Director – OKI Tri-State Chapter

mjeckerle@gmail.com

In cooperation with the Portland Chapter of Oregon

